Floatz logo

cs01

Locally Advanced or Metastatic Solid Tumors

Ruijin Hospitalmonoclonal_antibodyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Locally Advanced or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Atezolizumab
Genentech, Inc.
Phase 2B
Talzenna
Pfizer
Phase 2CCC
Cyclophosphamide
Exelixis
Phase 1/2CCC
Garsorasib
Suzhou Genhouse Bio Co., Ltd.
Phase 2CCC
cvl237 tablets
Convalife (Shanghai) Co., Ltd.
Phase 2CCC

View all 46 →

Same molecule, other indications

cs01 is also rated in:

ORR,OS,PFSDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →